Switch theme
Sign up to access all valuation multiples
The Oncology Institute Inc offers oncology services committed to improving cancer prevention, diagnosis, treatment, research, and education. The company provides services including infusion centres. In-house dispensary, Outpatient blood transfusion, Outpatient stem cell transplant, financial counseling, clinical trials, comprehensive lab testing, and end-of-life counseling. The business operates in three operating segments dispensary, patients services and clinical trials and others. Key revenue is earned from providing patient services. Majority of revenue is from patients services.
2007
825
LTM Revenue $443M
LTM EBITDA -$20.5M
$418M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Oncology Institute has a last 12-month revenue (LTM) of $443M and a last 12-month EBITDA of -$20.5M.
In the most recent fiscal year, Oncology Institute achieved revenue of $393M and an EBITDA of -$50.9M.
Oncology Institute expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Oncology Institute valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $443M | XXX | $393M | XXX | XXX | XXX |
| Gross Profit | $67.9M | XXX | $54.0M | XXX | XXX | XXX |
| Gross Margin | 15% | XXX | 14% | XXX | XXX | XXX |
| EBITDA | -$20.5M | XXX | -$50.9M | XXX | XXX | XXX |
| EBITDA Margin | -5% | XXX | -13% | XXX | XXX | XXX |
| EBIT | -$46.7M | XXX | -$60.1M | XXX | XXX | XXX |
| EBIT Margin | -11% | XXX | -15% | XXX | XXX | XXX |
| Net Profit | -$53.7M | XXX | -$64.7M | XXX | XXX | XXX |
| Net Margin | -12% | XXX | -16% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $43.5M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of August 18, 2025, Oncology Institute's stock price is $4.
Oncology Institute has current market cap of $346M, and EV of $418M.
See Oncology Institute trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $418M | $346M | XXX | XXX | XXX | XXX | $-0.61 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of August 18, 2025, Oncology Institute has market cap of $346M and EV of $418M.
Oncology Institute's trades at 1.1x EV/Revenue multiple, and -8.2x EV/EBITDA.
Equity research analysts estimate Oncology Institute's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Oncology Institute has a P/E ratio of -6.4x.
See valuation multiples for Oncology Institute and 15K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $346M | XXX | $346M | XXX | XXX | XXX |
| EV (current) | $418M | XXX | $418M | XXX | XXX | XXX |
| EV/Revenue | 0.9x | XXX | 1.1x | XXX | XXX | XXX |
| EV/EBITDA | -20.4x | XXX | -8.2x | XXX | XXX | XXX |
| EV/EBIT | -9.0x | XXX | -7.0x | XXX | XXX | XXX |
| EV/Gross Profit | 6.2x | XXX | n/a | XXX | XXX | XXX |
| P/E | -6.4x | XXX | -5.3x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -13.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialOncology Institute's last 12 month revenue growth is 20%
Oncology Institute's revenue per employee in the last FY averaged $0.5M, while opex per employee averaged $0.1M for the same period.
Oncology Institute's rule of 40 is -2% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Oncology Institute's rule of X is 44% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Oncology Institute and other 15K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 20% | XXX | 20% | XXX | XXX | XXX |
| EBITDA Margin | -5% | XXX | -13% | XXX | XXX | XXX |
| EBITDA Growth | -99% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -2% | XXX | 7% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 44% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.5M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 29% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| National Healthcare Corp | XXX | XXX | XXX | XXX | XXX | XXX |
| Regis Healthcare | XXX | XXX | XXX | XXX | XXX | XXX |
| Maternus-Kliniken | XXX | XXX | XXX | XXX | XXX | XXX |
| Addus HomeCare | XXX | XXX | XXX | XXX | XXX | XXX |
| Amedisys | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Oncology Institute acquired XXX companies to date.
Last acquisition by Oncology Institute was XXXXXXXX, XXXXX XXXXX XXXXXX . Oncology Institute acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 65K+ M&A deals.
Start Free Trial| When was Oncology Institute founded? | Oncology Institute was founded in 2007. |
| Where is Oncology Institute headquartered? | Oncology Institute is headquartered in United States of America. |
| How many employees does Oncology Institute have? | As of today, Oncology Institute has 825 employees. |
| Who is the CEO of Oncology Institute? | Oncology Institute's CEO is Mr. Daniel Virnich. |
| Is Oncology Institute publicy listed? | Yes, Oncology Institute is a public company listed on NAS. |
| What is the stock symbol of Oncology Institute? | Oncology Institute trades under TOI ticker. |
| When did Oncology Institute go public? | Oncology Institute went public in 2021. |
| Who are competitors of Oncology Institute? | Similar companies to Oncology Institute include e.g. National Healthcare Corp, Regis Healthcare, Maternus-Kliniken, Addus HomeCare. |
| What is the current market cap of Oncology Institute? | Oncology Institute's current market cap is $346M |
| What is the current revenue of Oncology Institute? | Oncology Institute's last 12 months revenue is $443M. |
| What is the current revenue growth of Oncology Institute? | Oncology Institute revenue growth (NTM/LTM) is 20%. |
| What is the current EV/Revenue multiple of Oncology Institute? | Current revenue multiple of Oncology Institute is 0.9x. |
| Is Oncology Institute profitable? | Yes, Oncology Institute is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Oncology Institute? | Oncology Institute's last 12 months EBITDA is -$20.5M. |
| What is Oncology Institute's EBITDA margin? | Oncology Institute's last 12 months EBITDA margin is -5%. |
| What is the current EV/EBITDA multiple of Oncology Institute? | Current EBITDA multiple of Oncology Institute is -20.4x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
